Abstract
<h3>In Reply.—</h3> We are pleased that our study has promoted interest and controversy. Dr O'Brien is correct in urging further development of safe and effective nonperoral medications for rheumatic disorders. However, some of the points that he has raised need clarification. First, it was never our intent to denigrate the use of topical agents in treating rheumatic disorders. In fact, a recent report has shown efficacy and systemic absorption of trolamine salicylate cream in patients with rheumatoid arthritis treated with one application, in an open-labeled study.<sup>1</sup> For our double-blind controlled study, we realized that the difficulties were formidable in selecting a defined patient group with specific chronic pain disorders of soft tissue that would potentially respond to an agent like trolamine salicylate cream. Hence, we selected patients with osteoarthritis because of the ease of categorizing such a disorder. Although it is true that a significant percentage of our patients
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
